Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to bone and cartilage destruction and extra-articular complications, including atherosclerotic vascular disease and premature mortality [1] .
The receptor for advanced glycation end products (RAGE) has been implicated in the pathogenesis of RA through its ability to amplify inflammatory pathways [2] . RAGE, is a member of the immunoglobulin super family, encoded in the Class III region of the major histocompatibility complex [3] . This multiligand receptor has one V type domain, two C type domains, a transmembrane domain, and a cytoplasmic tail. The V domain has two N-glycosylation sites and is responsible for most (but not all) extracellular ligand binding [4] . The cytoplasmic tails are believed to be essential for intracellular signaling [5] .
Although first described as a receptor for AGEs, the products of non-enzymatic glycation and oxidation of proteins/lipids, later studies indicated that RAGE was also a signal transduction receptor for pro-inflammatory S100/calgranulins, amphoterin [or high mobility group box 1 (HMGB1)], amyloid peptide and sheet fibrils. Additionally, RAGE is a counter-receptor for Mac-1. These ligands may be generated and accumulate in diverse settings such as diabetes, renal failure, neurodegeneration, autoimmunity/inflammatory milieu, and aging [6] .
RAGE, functions as a master switch that induces sustained activation of nuclear factor-kappaB (NF-jB), suppresses a series of endogenous auto regulatory functions and converts long-lasting pro-inflammatory signals into sustained cellular dysfunction and disease. Its activation is associated with high levels of dysfunctioning proteins in body fluids and tissues, and strongly associated with a series of diseases from allergy and Alzheimer to rheumatoid arthritis and urogenital disorders [7] .
As regards RA, RAGE is expressed by many of the cells that participate in the development of RA, including macrophages, neutrophils and T cells. RAGE is expressed on macro-phages and T cells within synovial tissues of RA patients as well as on synovial fluid macrophages [8] . Synovial fibroblasts that account for about 50% of the cellular constituents of the synovial lining layer constitutively also express RAGE [9] .
Not only the RAGE but also its ligands have been investigated in arthritis. One of the RAGE ligand HMGB1 is over expressed in inflammatory arthritis with a consequence of RAGE binding resulting in macrophage stimulation, induction of TNF-a and IL-6, maturation of DCs, Th1 cell responses, stimulation of CD4+ and CD8+ cells, and amplification of response to local cytokines occurs [10] .
Several RAGE ligands are characteristically overexpressed in RA. High concentrations of three of its putative pro-inflammatory ligands, S100A8/A9 complex (calprotectin), S100A8, and S100A12, are found in rheumatoid arthritis (RA) serum and synovial fluid [11] .
RAGE binding to pro-inflammatory ligands, including members of the S100/calgranulin family, and high mobility group box chromosomal protein 1 (HMGB1), is implicated in cell signaling by synergizing with DNA CpG motifs [12, 13] .
Soluble C-truncated RAGE (sRAGE) lacks the transmembrane and cytosolic domains of the full-length receptor, is a secretory splice isoform which can prevent pro-inflammatory effects of RAGE signaling by acting as a decoy by removal/ neutralization of circulating ligands [14] .
Increasing the production of plasma sRAGE is therefore considered to be a promising therapeutic target that has the potential to prevent multiple diseases [15] . Clinical studies have shown that higher plasma levels of sRAGE are associated with a reduced risk of coronary artery disease [6] , hypertension [16] , arthritis [17] and Alzheimer's disease [18] . In a collagen-induced arthritis (CIA) murine model, treatment with murine sRAGE significantly reduced joint inflammation and destruction [19] . It has previously been shown that a polymorphism of the gene encoding RAGE located within the V-type immunoglobulin domain of RAGE, which results in a glycine to ser-ine substitution at amino acid position 82, is in linkage disequilibrium with HLA-DR4 [20] , it was therefore not surprising that the Ser82 allele was increased in RA subjects [19] .
It is conceivable that this, or other linked polymorphisms in the RAGE gene affect splicing of the C-truncated, endogenously secreted form of the receptor, or susceptibility to cell surface RAGE cleavage by matrix metalloproteinase thus altering the ratio of soluble to membrane RAGE [11] .
The aim of this study is to evaluate the levels of sRAGE in RA patients and to detect the gene polymorphism and to assess the relationship between sRAGE levels and disease characteristics.
Patients and methods
The study included 33 patients (26 females and 7 males) with RA who fulfilled the ACR criteria for diagnosis of RA [21] . All patients were recruited from the Rheumatology Department, Cairo University Hospitals. Sixteen healthy normal subjects with matched age and sex were enrolled as controls. Informed consent was obtained from all subjects.
All patients were subjected to full assessment including: 
Detection of sRAGE level
Soluble RAGE determination by enzymatic immunoassay by kit supplied by R&D Systems (Minneapolis, MN, USA) according to manufacturer recommendation [24] .
Genotyping
Molecular study of single nucleotide polymorphisms (SNP) in the glycine82serine (G82S) polymorphism of the RAGE gene for genotyping was done. Genomic DNA was extracted and then genotyped by polymerase chain reaction/restriction fragment length polymorphism (PCR and RFLP). The affected exon considered was amplified by PCR and the products were digested with appropriate restriction enzyme fragment were finally size fractionated on agarose gel to allow allele assignment. DNA was extracted from whole blood using DNA extraction kit (BioRad, Italy) The average DNA concentration was determined by absorbance at 260 nm using Perkin Elmer spectrophotometer and the integrity of the DNA was checked by electrophoresis on 0.8% agarose gel with an ethidium bromide. The affected exon considered was amplified by PCR in 50 ll reaction mixture consisting of 67 mM Tris-HCl (pH 8.8), 1 mM magnesium chloride, 10 mM dNTPs, 5 pmol of each primer -sense primer: 5 0 -GTAAGCGGGGCTC-CTGTTGCA-3 0 ; antisense primer: 5 0 -GGCCAAGGCTGGG-GTTGAAGG-3 0 , 100 ng of extracted DNA and 2.5 units of Taq DNA polymerase (Amersham Pharmacia Biotech.). PCR was carried out in thermal cycler (Hybaid) with 35 cycle of denaturation for 1 min at 94°C and annealing for 1 min at 58°C and extension for 1 min at 72°C with final extension step 72°C for 10 min. To detect glycine82serine (G82S) polymorphism of the RAGE gene, the PCR product was then digested with Alu I (Life Technologies) restriction enzyme. For digestion 17 ll of PCR product, 2 ll of buffer and 10 ll of restriction endonuclease (10 unit/ll) were mixed and incubated for 12 h at 37°C. Digested DNA product was separated by electrophoresis in 2.5% agarose gel stained with ethidium bromide and visualized by UV transilluminator [25] .
Statistical analysis
Data were coded and entered using the statistical package SPSS version 12. Data were summarized using mean and standard deviation for quantitative variables and percent for qualitative variables. Comparisons between groups were performed using Chi-square test for qualitative variables and independent sample t-test and analysis of variance (ANOVA) for normally distributed quantitative variables. While non-parametric Mann-Whitney test and Kruskal-Wallis test were used for abnormally distributed quantitative variables. Correlation was done to test for linear relations between quantitative variables. Linear regression analysis was done to find significant predictors of sRAGE levels. In all cases p value <0.05 was considered to be statistically significant.
Results

Basic demographic, clinical and laboratory data
The age of patients ranged between 20 and 66 years with a mean of 45.44 ± 11.68 years. The age at disease onset ranged between 15 and 64 years with a mean of 39.44 ± 11.31 years. The disease duration (defined as the interval in years between the appearance of the first manifestation related to RA and the time at which the study started) extended between 1 and 18 years with a mean of 6.0 ± 4.61 years. The morning stiffness time ranged from 0-5 h with a mean of 0.78 ± 1.09. Four patients were diabetics; six were hypertensive, five patients with cardiac disease (ischemic heart disease) and three with chest disease (interstitial lung fibrosis). RF was positive in 24 patients (72.7%) and was negative in all controls. CRP was significantly higher in RA patients as compared with controls (4.71 ± 2.2 versus 2.11 ± 1.1, p < 0.01). The DAS28-ESR mean was 3.38 ± 1.06.
Serum levels of sRAGE
We observed the decreased levels of serum sRAGE in RA patients than controls (840.11 ± 230.32 pg/ml versus 1111.59 ± 143.20 pg/ml). The difference was significantly lower as p < 0.05. This is shown in Fig. 1 .
Genotyping of the receptor of advanced glycation end products
The results of molecular study for genotyping of the RAGE gene showed polymorphisms in the glycine82serine (G82S) in 22 out of 33 RA patients, 5 of them were homozygous for the RAGE serine82 allele and 17 were heterozygous. Genotyping of the RAGE gene in the control subjects showed polymorphisms in the G82S in 5 out of 16, only one of them was homozygous for the RAGE serine82 allele and the other four were heterozygous. The difference in gene polymorphism between cases and controls did not reach statistical significant levels.
Correlation between sRAGE level, clinical and laboratory data of RA patients
The sRAGE levels were significantly lower in RA patients with more disease activity as indicated by MS, TJC and CRP (p values were <0.05). This is shown in Table 1 .
Studying the relation between sRAGE, RF and associated extra-articular manifestations of RA patients
This showed that sRAGE levels were significantly lower in RA patients with Sjogren's syndrome than those without this syndrome and in patients with cardiac disease. This is shown in Table 2 .
Significant predictors for sRAGE level
Linear regression analysis was done to detect significant predictors for sRAGE as shown in Table 3 . The significant predictors found included CRP and gene polymorphism.
The relation between gene polymorphism and clinical and laboratory data of RA patients
The glycine82serine (G82S) allele was related to MS, CRP and sRAGE level. We did not identify correlation between gene polymorphism and any other data as shown in Table 4 .
The relation between gene polymorphism, RF and associated extra-articular manifestations of RA patients
This showed that the glycine82serine (G82S) allele is more common in patients with cardiac affection ( Table 5 ).
Discussion
The results of the current study showed decreased serum levels of sRAGE in a cohort of patients with RA than the normal subjects and the levels were significantly lower in RA patients with more disease activity and in those who carried the polymorphisms in the glycine82serine (G82S) allele. This was similar to Pullerits et al., who reported that the plasma levels of sRAGE to be reduced in subjects with rheumatoid arthritis compared with healthy controls or subjects with non-inflammatory joint disease. These findings suggest the possibility that levels of sRAGE might be a biomarker of inflammation [17] .
The receptor for advanced glycation end products (RAGE) interacts with distinct ligand families linked to the inflammatory response. Studies in animal models suggest that RAGE is up regulated in the inflamed joint and that blockade of the receptor, using a ligand decoy soluble form of RAGE (sRAGE), attenuates joint inflammation and expression of inflammatory and tissue-destructive mediators [26] .
In RA, there is a wide diversity of RAGE ligands present in the inflamed joints, as well as in the circulation, that could lead to the binding and consumption of sRAGE during the inflammatory process. One of the high-affinity ligands for RAGE/ sRAGE is HMGB1, a potent cytokine playing an important role in the pathogenesis of chronic inflammation. HMGB1 is a potent trigger of arthritis and its expression is increased in synovial tissue of RA patients as well as in experimental arthritis [27] . HMGB1 levels in the synovial fluid and sera of RA patients are significantly elevated as compared with levels in osteoarthritis patients [28] . It is thus probable that sRAGE may form in vivo complexes with HMGB1 in the sera/synovial fluid of RA patients, leading to inaccurately low levels of sRAGE.
Other ligands such as S100A8/A9 (calprotectin) and S100A12 (calgranulin C, EN-RAGE) levels are significantly elevated in serum and synovial fluid from RA patients compared to healthy normal donors [2, 29] . S100A8/A9 levels are also higher in supernatants of cultured RA synoviocytes than of osteoarthritis synoviocytes [30] . Vyta´sˇek et al. reported the increased level of specific glycation end products in sera of patients with rheumatoid arthritis [31] .
The presence of high levels of these soluble ligands in RA patients provides a basis for increased consumption of the sRAGE by interaction, followed by elimination of such sRAGE-ligand complexes via the reticuloendothelial system [32] .
In our study, linear regression analysis showed that gly-cine82serine (G82S) polymorphism in the RAGE gene to be significant predictor of the serum level of sRAGE which is similar to Chen et al. who postulated that the polymorphism in the RAGE gene at this site may cause altering the ratio of soluble to membrane RAGE [11] .
The current study showed that, there is significant decrease in levels of sRAGE with increased disease activity as indicated by increased duration of MS, increased TJC and increased CRP levels. Similarly Soluble RAGE levels were negatively associated with serum levels of C-reactive protein (CRP) [11] . Taken together the decrease in the level of sRAGE and the association with markers of disease activity, it was suggested that sRAGE may block the ligand-RAGE interaction on the cell surface by directly binding leukocyte b2-integrin Mac-1 and thereby decreasing influx of inflammatory cells into the joint cavity, functioning as an immune surveillance mechanism. Lower levels of sRAGE detected in RA patients might thus increase the propensity towards inflammation since RAGE ligands have better access to cell membrane-bound receptor, the binding of which leads to the activation of inflammatory pathways. The treatment with methotrexate was shown to counteract this pro-inflammatory feature in patients with RA [17] . In our study we were not able to examine the effect of the medications as all our patients were receiving methotrexate.
Our results showed that, there is decreased level of sRAGE in RA patients with Sjogren's syndrome than RA patients without Sjogren's syndrome. The immunohistochemical expression and immunoblotting of RAGE in labial salivary glands from Sjogren's syndrome patients were investigated. RAGE is present in the labial salivary glands of both normal and Sjogren's syndrome, with preliminary data suggesting over-expression in tissues from Sjogren's syndrome patients [33] . Further our results also showed that there is decreased level of sRAGE in RA patients with cardiac disease than those without cardiac affection. Cardiovascular (CV) disease is increased in patients with chronic inflammatory disease, including RA. Furthermore it has become clear at a pathophysiological level, that atherosclerosis has striking similarities with autoimmune disease. The receptor for advanced glycation end products (RAGE) has been identified as a candidate molecule influencing response to ongoing inflammation and autoimmunity [34] . Soluble RAGE was found to be associated not just with RA inflammation and autoantibody production, but also with classical vascular risk factors for endorgan damage [11] . Moreover in this study the gene polymorphism was also correlated to cardiovascular symptoms. Consistent with its role as a RAGE decoy molecule, these data suggested that RAGE activity influences co-development of joint and vascular disease in rheumatoid arthritis patients. Pointing to the relation of sRAGE in cardiovascular assessment the study of non-diabetic men with and without coronary artery disease showed lower levels of plasma sRAGE in these subjects which correlated with the highest incidence of coronary artery disease [35] .
In contrary to our study Gly82Ser polymorphism in the RAGE gene (RAGE 82Ser) occurred more frequently in RA patients than in healthy controls [19] . In the current study the comparison of the glycine82serine (G82S) polymorphism between RA patients and healthy controls didn't reach statistical significant levels. Larger group size may figure out this difference.
In this study gene polymorphism is related to disease activity as indicated by MS and CRP in RA patients, in contrary to others who did not find any relation between the polymorphism and higher levels of inflammation [31] .
The sRAGE levels were decreased in patients with rheumatoid arthritis than the healthy subjects and this decrease was correlated with the gene polymorphism which may be a causative effect and it was also correlated with markers of disease activity which may point to its protective role in the severity of joint inflammation. The association found between the gene polymorphism, the level of sRAGE and cardiovascular disease suggested that RAGE activity influences co-development of joint and vascular disease in rheumatoid arthritis patients. 
